Shouyao Holdings (Beijing) Co., LTD. (SHA:688197)
42.94
-0.85 (-1.94%)
At close: May 12, 2026
SHA:688197 Revenue
Shouyao Holdings (Beijing) Co., LTD. had revenue of 28.00M CNY in the quarter ending March 31, 2026, with 1,300.00% growth. This brings the company's revenue in the last twelve months to 34.67M, up 483.43% year-over-year. In the year 2025, Shouyao Holdings (Beijing) Co., LTD. had annual revenue of 8.67M with 119.88% growth.
Revenue (ttm)
34.67M
Revenue Growth
+483.43%
P/S Ratio
187.85
Revenue / Employee
201.56K
Employees
172
Market Cap
6.51B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 8.67M | 4.73M | 119.88% |
| Dec 31, 2024 | 3.94M | -1.29M | -24.61% |
| Dec 31, 2023 | 5.23M | 3.40M | 186.18% |
| Dec 31, 2022 | 1.83M | -11.21M | -85.98% |
| Dec 31, 2021 | 13.03M | 6.01M | 85.67% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Suzhou Fengbei Biotech Stock | 3.61B |
| Anhui Huaheng Biotechnology | 2.95B |
| Novogene | 2.26B |
| Xiangxue Pharmaceutical | 1.53B |
| Shenzhen Weiguang Biological Products | 1.26B |
| Wuhan Keqian Biology Co.,Ltd | 932.09M |
| R&G PharmaStudies | 896.26M |
| Jiangsu Aidea Pharmaceutical Group | 699.33M |